What Is 5-Amino-1MQ?

1. How does 5-Amino-1MQ work?

NNMT transfers a methyl group from S-adenosylmethionine, abbreviated SAM, onto nicotinamide, a form of vitamin B3. The products are 1-methylnicotinamide and S-adenosylhomocysteine. Nicotinamide can also enter the salvage pathway that recycles it into NAD+, a coenzyme involved in energy metabolism and cellular repair.

That creates two connections researchers can investigate. NNMT uses a potential NAD+ precursor, and it consumes methyl groups that cells also use elsewhere. Blocking the enzyme can change both processes. Describing NNMT as directly “breaking down NAD+” skips the actual reaction: its substrate here is nicotinamide.

In Kraus and colleagues’ 2014 Nature paper, reducing NNMT expression with antisense oligonucleotides protected mice against diet-induced obesity. Researchers linked the effect to higher energy expenditure and changes in adipose NAD+, SAM and polyamine metabolism. Polyamines are small molecules involved in cell function; making and processing them can consume metabolic fuel.

That experiment tested suppression of a gene’s expression. Researchers subsequently tested whether a small molecule could inhibit the enzyme’s activity and produce useful effects. 5-Amino-1MQ came from that drug-development work.

2. The 5-Amino-1MQ weight-loss study, in numbers

Neelakantan and colleagues’ paper appeared online in 2017 and in the January 2018 issue of Biochemical Pharmacology. Those two dates can make the same study look like two separate experiments in online summaries.

The obesity experiment included 18 male mice, nine per group, after 16 weeks on a high-fat diet. Researchers continued that diet and administered either saline or 5-Amino-1MQ by subcutaneous injection for 11 days.

The fat-pad result cannot be relabeled “35% total body-fat loss.” Researchers weighed a specific depot after treatment; they did not report a 35% reduction in each mouse’s whole-body fat from baseline. Likewise, the 5.1% weight decrease and the comparison against weight-gaining controls use different denominators.

Unchanged measured food intake supports investigating an effect beyond eating less. It does not demonstrate that people can take 5-Amino-1MQ, keep their usual calorie intake and reliably lose fat. Nine mice per group over 11 days cannot establish lasting effects, weight regain after withdrawal or outcomes in lean athletes.

Why the mouse dose is easy to misquote

The methods report 20 mg/kg per injection, three times daily. They also express the daily amount as approximately 34 mg/kg of the parent compound after accounting for the salt’s mass. These are two descriptions of the same experimental exposure.

Neither value supplies a human dose. Converting milligrams by body weight would still leave absorption, metabolism, tissue exposure and toxicity unanswered. The experiment also says nothing directly about whether an oral capsule reproduces those injection results.

3. Which studies concern the compound, the target or people?

NNMT research spans genetic experiments, several drug candidates and measurements in human tissue. A paper about NNMT is not automatically a treatment study of 5-Amino-1MQ.

The human study by Kannt and colleagues found approximately twice as much NNMT expression in two types of white adipose tissue in participants with type 2 diabetes compared with controls. Exercise and bariatric surgery were associated with lower adipose NNMT expression. Nobody in that study received 5-Amino-1MQ.

For this guide, searches of PubMed, Europe PMC and ClinicalTrials.gov used the short name and related chemical terminology. On September 21, 2026, the registry returned no matches for “5-amino-1MQ” or “5-amino-1-methylquinolinium”; the literature reviewed did not identify a published human treatment trial. These searches describe the public evidence found, without ruling out unpublished work or studies registered under other names.

4. NAD+, energy and longevity claims

In the original fat-cell experiments, NAD+ measurements were roughly 1.2–1.6 times those in untreated cells across the tested 1–60 micromolar concentration range. The individual comparison reached statistical significance at 10 micromolar. These were cultured mouse adipocytes, so “raises NAD+ by 60%” would need that context attached.

An increase in a cellular coenzyme does not quantify how energetic a person feels, their exercise performance or their lifespan. The studies reviewed here do not establish human improvements in fatigue, VO₂ max, biological age or survival from taking 5-Amino-1MQ.

NMN and NR enter NAD+ precursor pathways, while 5-Amino-1MQ inhibits an enzyme that uses nicotinamide. The mechanisms make combinations a research question. They do not establish that stacking these compounds raises useful tissue NAD+ more effectively or produces better health outcomes. A change in a blood marker would also need evidence connecting it to the outcome someone wants.

5. Muscle preservation, recovery and bodybuilding

The 2019 muscle paper tested 24-month-old male mice. Researchers injured the tibialis anterior, a lower-leg muscle, with barium chloride and examined recovery with NNMT inhibition. Treatment began before the injury.

Treated mice had greater muscle stem-cell activity and larger regenerating fibers. The paper reported about 70% higher peak torque in the injured muscle compared with controls. Torque measures rotational force; here it assessed recovery of muscle function after a controlled chemical injury.

That result gives researchers a reason to investigate age-related repair problems. It cannot predict a 70% strength increase in a healthy lifter. The experiment did not test hypertrophy from resistance training, soreness after a workout or preservation of lean mass while using a GLP-1 drug.

For body recomposition, the missing experiment would measure fat mass, lean mass and performance during a defined calorie deficit. A lower scale weight in obese mice and better repair in a separate injury study cannot jointly establish muscle-sparing fat loss in people.

6. Oral 5-Amino-1MQ, injections and half-life

The original paper included artificial-membrane and intestinal-cell permeability tests. Those assays help screen whether molecules can cross barriers, but cannot measure how much of a swallowed dose reaches human circulation or adipose tissue.

A separate 2018 Kannt study reported about 40% oral bioavailability in mice for JBSNF-000088. That molecule is a different NNMT inhibitor. Its absorption and roughly 0.4-hour apparent oral half-life cannot be assigned to 5-Amino-1MQ.

The evidence reviewed here does not establish a human oral or injected half-life for 5-Amino-1MQ. There is consequently no validated basis for a once-daily schedule, split dosing, a loading phase or a particular cycle length. A half-life calculator can model an assumption; it cannot supply the missing pharmacokinetic study.

7. Side effects and safety gaps

The short obesity study reported no observable adverse effects under its experimental conditions. That observation is useful for early drug development, but cannot estimate how often a person might develop an adverse effect or whether months of exposure would be tolerated.

Reliable human adverse-event rates, interaction studies and reproductive safety data were not established in the research reviewed. Lists of supposedly “common” side effects copied from sellers or forums have no controlled denominator. Absence of a dependable side-effect list leaves uncertainty about risk.

NNMT participates in both nicotinamide and methyl-group metabolism. The mechanistic research describes changes in SAM availability and histone methylation, chemical modifications involved in gene regulation. That makes the biological effects broader than one fat-loss measurement. It does not, by itself, prove benefit or harm from chronic human inhibition.

Product testing answers a separate question. A certificate of analysis may provide information about the tested sample’s identity or purity, depending on its methods. It cannot establish an effective human dose, clinical safety or the sterility of an injectable preparation unless those properties were specifically assessed.

8. 5-Amino-1MQ vs GLP-1 drugs, MOTS-c and NAD+ precursors

No controlled human evidence identified here establishes added benefit or safety from combining 5-Amino-1MQ with semaglutide, tirzepatide or retatrutide. Claims about breaking a plateau, preserving muscle or preventing metabolic adaptation remain untested for those combinations.

Before-and-after photos cannot resolve that uncertainty. Changes in diet, training, other compounds, hydration and starting body fat can all affect the apparent result. A useful human trial would specify the formulation and dose, compare treatment against a control, measure body composition and collect adverse events. For a muscle-preservation claim, it would also need lean-mass and strength outcomes during weight loss.

9. 5-Amino-1MQ FAQ

• What is 5-Amino-1MQ used for?

  Researchers use 5-Amino-1MQ to investigate NNMT inhibition, fat metabolism and muscle regeneration. People discuss it for fat loss, NAD+ support and body recomposition, but those benefits have not been established in human treatment trials.

• Is 5-Amino-1MQ a peptide?

  No. 5-Amino-1MQ is 5-amino-1-methylquinolinium, a small molecule commonly studied as an iodide salt. It has no chain of amino acids, even though sellers often group it with peptides.

• How much weight can you lose with 5-Amino-1MQ?

  There is no established human weight-loss estimate. A short mouse study reported about 5.1% weight loss from baseline after 11 days of injections. That result cannot predict pounds lost by a person or the effects of oral capsules.

• Does 5-Amino-1MQ increase NAD+?

  Researchers measured increased NAD+ in cultured mouse fat cells exposed to 5-Amino-1MQ. The result supports a cellular mechanism; it does not establish increased NAD+ in human muscle, better energy or longer life after taking it.

• What is the recommended 5-Amino-1MQ dosage?

  No clinically validated human dose, cycle or titration schedule has been established. Mouse injection doses and doses advertised for capsules cannot supply a tested human regimen.

• Does oral 5-Amino-1MQ work?

  The original paper included laboratory membrane-permeability tests, but its obesity experiment used injections. This guide found no human oral study establishing absorption, fat loss or an effective capsule dose.

• What are the side effects of 5-Amino-1MQ?

  Reliable human side-effect frequencies and long-term safety data are unavailable. Short mouse studies reported no obvious adverse effects under their conditions; they cannot establish the safety of repeated human use.

• What is the half-life of 5-Amino-1MQ?

  A dependable human elimination half-life has not been established in the research reviewed here. A laboratory permeability result or a half-life from a different NNMT inhibitor cannot determine a dosing interval.

• Can you stack 5-Amino-1MQ with tirzepatide or retatrutide?

  The reviewed evidence does not establish the safety or added benefit of either combination. Different proposed mechanisms do not demonstrate extra fat loss, muscle preservation or a safe dose ratio.

10. Sources